June 8, 2021
The US FDA granted historic approval to Biogen/Eisai’s controversial Alzheimer’s drug aducanumab on June 7, making it the first-ever disease-modifying therapy that slows the progression of the memory-robbing illness. The US regulator tapped its accelerated approval pathway to green light...read more